Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerance of haploidentical NK cell infusion after autologous stem cell transplantation in multiple myeloma
IRCT20140818018842N46Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2025
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of haploidentical natural killer cells in multiple myeloma (MM) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: NK cell treatment tolerance. Started Feb 2025; status: completed.
02
Drugs
haploidentical natural killer cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on IRCT20140818018842N46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N46.